adalimumab-adbm Cyltezo
Selected indexed studies
- Adalimumab-Adbm: The First Interchangeable Biosimilar for the Treatment of Inflammatory Diseases. (Ann Pharmacother, 2022) [PMID:35392668]
- Immunogenicity of adalimumab reference product and adalimumab-adbm in patients with rheumatoid arthritis, Crohn's disease and chronic plaque psoriasis: a pooled analysis of the VOLTAIRE trials. (BMJ Open, 2024) [PMID:39551590]
- Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity. (Br J Clin Pharmacol, 2020) [PMID:32363771]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- AVT02: An Adalimumab Biosimilar. (2022) pubmed
- FKB327: An Adalimumab Biosimilar. (2019) pubmed
- GP2017: An Adalimumab Biosimilar. (2018) pubmed
- Adalimumab-Adbm: The First Interchangeable Biosimilar for the Treatment of Inflammatory Diseases. (2022) pubmed
- Immunogenicity of infliximab and adalimumab. (2019) pubmed
- Adalimumab Monotherapy vs Adalimumab With Methotrexate for Psoriasis. (2025) pubmed
- Immunogenicity of adalimumab reference product and adalimumab-adbm in patients with rheumatoid arthritis, Crohn's disease and chronic plaque psoriasis: a pooled analysis of the VOLTAIRE trials. (2024) pubmed
- Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity. (2020) pubmed
- Relative bioavailability, immunogenicity, and safety of two adalimumab-adbm formulations in healthy volunteers: a double-blind, randomized, single-dose, parallel-arm Phase I trial (VOLTAIRE-HCLF). (2024) pubmed
- Adalimumab-Associated Hemorrhagic Pericarditis. (2020) pubmed